BeyondSpring (BYSI)
(Delayed Data from NSDQ)
$2.43 USD
+0.14 (6.11%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.42 -0.01 (-0.41%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BYSI 2.43 +0.14(6.11%)
Will BYSI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BYSI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BYSI
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
BYSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
Other News for BYSI
iBio, Mesoblast, Kodiak Sciences among healthcare movers
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP
BeyondSpring Announces Executive Leadership Change
12 Health Care Stocks Moving In Thursday's Intraday Session